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Abstract Rationale: Schizophrenia has been associated
with dysregulation of dopamine (DA) transmission and
impairment in a number of experimental tasks, including
sensorimotor gating assessed using prepulse inhibition
(PPI) and selective attention assessed using latent inhibi-
tion (LI). We have demonstrated in previous studies that
after withdrawal from escalating (ESC) dosages of am-
phetamine (AMPH), animals exhibited disruption of LI
but no alteration of PPI. Moreover, these animals always
showed behavioural sensitization to an AMPH challenge.
Objective: In this study, we were interested in testing
whether a different administration schedule would elicit
disruption of both LI and PPI. Methods: Animals were
treated with continuous AMPH release (via osmotic mini-
pumps at a dosage of 10 mg kg−1 day−1 for 7 days) and
tested for their performance in LI and PPI during
withdrawal in a drug free state. Rats received AMPH
treatment during the induction phase in their home cages
or in the activity chambers. Following withdrawal, the ex-
pression of behavioural sensitization to an AMPH chal-
lenge was tested in both cases in the activity chambers.
Results: Animals pretreated with AMPH from both groups
did not exhibit behavioural sensitization. Withdrawal from
continuous administration induced LI attenuation with no
effect on PPI. Conclusions: These findings are similar to
what was previously found with respect to an ESC AMPH
regime. The only difference between the schedules was that
the ESC AMPH schedule led to behavioural sensitization
whereas the continuous AMPH did not. It is suggested that
the expression of sensitization may not be a prerequisite for
observed LI disruption.
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Introduction
One of the leading views on the pathophysiology of schizo-
phrenia contends that the unmedicated schizophrenic brain
is characterized by an endogenous sensitized dopaminergic
system. Recent positron emission tomography (PET) and
single-photon emission computerized tomography (SPECT)
imaging techniques examining the displacement of a radio-
active D2 receptor binding ligand by endogenously released
dopamine (DA) have revealed that untreated schizophrenic
patients show enhanced striatal DA release in response to
an acute amphetamine (AMPH) challenge administration
(i.e. a sensitized response) (Laruelle 2000). Moreover, the
DA release was positively correlated with the severity of
their positive symptoms, supporting an endogenous sensi-
tization hypothesis of at least the positive symptoms of
schizophrenia (Abi-Dargham et al. 1998; Laruelle 2000;
Laruelle et al. 1999).
In experimental animals, injections of AMPH are known
to induce a state of behavioural sensitization (Kalivas and
Stewart 1991; Robinson and Becker 1986). Behavioural
sensitization consists of two distinct phases, termed in-
duction and expression. The induction of behavioural sen-
sitization to psychostimulants is defined as the transient
sequence of cellular and molecular events precipitated by
repeated psychostimulant administration that lead to the
enduring changes in neuronal function responsible for the
expression of behavioural sensitization (Kalivas and
Stewart 1991). The expression of behavioural sensitization
is indicated by an augmentation of behaviours (e.g. loco-
motion, stereotypes) (Kalivas et al. 1993; Robinson and
Becker 1986) combined with enhanced striatal DA release
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(Kalivas and Stewart 1991) to subsequent drug challenges
and can persist even after prolonged periods of abstinence.
Over the last few years, our laboratory has attempted to
develop an animal model of schizophrenia based on the
endogenous sensitization hypothesis. To mimic symptoms
of schizophrenia in rats, we exposed them repeatedly to
AMPH and tested the sensitized animals following varying
periods of withdrawal, without further exposing them to
any challenge administration. We evaluated AMPH with-
drawal following a variety of administration schedules
(Murphy et al. 2001a,b; Russig et al. 2002, 2003a,b, 2005)
and examined the animals in a number of behavioural
paradigms relevant to schizophrenia, in particular latent
inhibition (LI) and prepulse inhibition (PPI). LI refers to
the observation that repeated exposure to a stimulus with-
out consequence comes to impede the formation of sub-
sequent associations with that stimulus (Lubow 1973). PPI
is a phenomenon whereby low-to-moderate intensity
prepulse stimuli attenuate startle responses to a subsequent
intense pulse (Graham 1975; Hoffman and Ison 1980;
Hoffman and Searle 1965). Reductions in both LI and PPI
have been reported in schizophrenic patients (Baruch et al.
1988; Braff et al. 1978, 2001; Braff and Geyer 1990; Gray
et al. 1995; Swerdlow et al. 1996; Weiner and Feldon
1997). These deficits can be reversed by neuroleptic treat-
ment in both humans (Baruch et al. 1988; Braff et al. 2001;
Gray et al. 1992, 1995; Kumari and Sharma 2002; Kumari
et al. 1999, 2002; Leumann et al. 2002) and animals
(Mansbach et al. 1988; Swerdlow et al. 1991; Warburton et
al. 1994; Weiner et al. 1996). Since LI and PPI can be
similarly tested in both humans and animals (Baruch et al.
1988; Braff et al. 1978, 2001), they can therefore be con-
sidered as translational paradigms relevant for testing
schizophrenia-like symptoms in animals and for detecting
new antipsychotic drugs. Thus, pharmacological and phys-
iological manipulations that induce LI and PPI deficits are
used to model schizophrenic patients’ inability to ignore
irrelevant stimuli and sensorimotor gating impairments,
respectively (Geyer et al. 1990; Weiner and Feldon 1997).
To develop an animal model of schizophrenia, we have
previously characterized the behavioural consequences of
withdrawal from an intermittent (five daily injections of
1.5 mg/kg) and an escalating (ESC; 6 days with three daily
injections of 1.0–5.0 mg/kg) AMPH schedule. We found
that the different schedules of AMPH administration pro-
duce opposite effects on LI. Our findings indicated that
withdrawal from intermittent administration resulted in
enhanced LI (Murphy et al. 2001a) while ESC adminis-
tration eliminated LI following various withdrawal periods
(Murphy et al. 2001b; Russig et al. 2002, 2003b). Fur-
thermore, we provided substantial support for the predict-
ive validity of the ESC AMPH schedule model by showing
that the disrupted LI can be reversed following treatment
with either the typical antipsychotic haloperidol or the
atypical antipsychotic clozapine (Russig et al. 2002). Our
studies further demonstrated that following long periods of
withdrawal, these previously drug-free tested animals were
indeed sensitized in their responses both to low (Russig et
al. 2003a,c, 2005) and high (2003c) dosages of an AMPH
challenge administration. In contrast to the rather persistent
and enduring effects on LI both AMPH schedules did not
affect PPI (Murphy et al. 2001b; Russig et al. 2003b). Even
when PPI was tested following a subthreshold dosage of a
DA agonist challenge, such as apomorphine or AMPH,
AMPH-withdrawn animals exhibited normal PPI (Russig
et al. 2003b).
Withdrawal from AMPH administration has also been
used as an animal model of depression (Barr et al. 1999;
Barr and Phillips 1999, 2002; Lin et al. 1999, 2000; Russig
et al. 2003c). In this context, however, the animals dem-
onstrate ‘depressive-like’ symptoms only during the early
drug withdrawal period (2–5 days). Recently, two studies
(Cryan et al. 2003; Paterson et al. 2000) found that during
short-term withdrawal from a continuous AMPH admin-
istration delivered via osmotic mini-pumps, stronger anhe-
donia (i.e. elevations in brain reward thresholds) was
observed compared to withdrawal from repeated AMPH
administration (Lin et al. 1999). However, in contrast to the
short-term effects of withdrawal from AMPH (that were
already diminished on day 5 of withdrawal) (Lin et al.
1999; Paterson et al. 2000) studied in several depression-
related paradigms, it was shown by us and others that there
are withdrawal effects lasting for a much longer (up to
63 days subsequent to last injection) time in paradigms
related to schizophrenia such as LI (Murphy et al. 2001b;
Tenn et al. 2005) and PPI disruptions (Peleg-Raibstein et al.
2005a,b; Tenn et al. 2005). With these observations in
mind, we sought to find a drug administration regime that
would be most appropriate for producing an improved
animal model of schizophrenia.
Accordingly, we decided to use a continuous AMPH
administration method in experiment 1. This was done to
evaluate the consequences of withdrawal on both PPI and
LI. We chose a dosage of 10 mg kg−1 day−1 for seven con-
secutive days. This election was made to enable a com-
parison with the ESC AMPH schedule employed in our
laboratory, which had a total dose of 75 mg AMPH leading
to LI disruption but which left PPI intact. Since animals
that were pretreated with AMPH exhibited LI attenuation,
we examined a subgroup of animals in post-mortem neuro-
chemistry in an attempt to characterize the underlying
neurochemical mechanisms of disrupted LI. These animals
participated in the LI and PPI parts of the study but were
not exposed to AMPH challenge for evaluation of the
expression of sensitization.
In experiment 1, animals received drug treatment in their
home cage. The expression of behavioural sensitization was
tested in a different environment (in an activity chamber).
Under these conditions, AMPH-pretreated animals did not
express behavioural sensitization. This result was expected
since it is known that this method of drug administration
does not produce sensitization to a subsequent AMPH
challenge (Robinson and Becker 1986).
In experiment 2, we were interested to ascertain whether
drug administration, during the induction phase and in the
same environment as the one used for testing, would
facilitate the expression of behavioural sensitization tested
in the same test environment. Hence, we had two main
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reasons for carrying out the second experiment. First, we
were interested in evaluating a dose-dependent response of
AMPH on locomotor activity during the 7-day period of
continuous drug release in the induction phase. In this
experiment, animals were kept in activity chambers
throughout the entire drug-release period. Locomotor
activity was monitored continuously during the course of
the treatment. Second, we sought to evaluate whether this
environment, previously paired with drug treatment, had an
influence on the expression of behavioural sensitization.
Therefore, animals were tested on withdrawal day 77 for
sensitization of locomotor activity in response to an AMPH
challenge in the same activity chambers.
Materials and methods
Subjects
Male Wistar rats (bred at the animal facilities of the
Behavioural Neurobiology Laboratory, Schwerzenbach,
Switzerland) weighing 300–350 g at the time of surgery
(experiment 1, 26 rats; experiment 2, 24 rats) were used.
The rats were housed under reversed light–dark cycle
(lights on between 1900 and 0700 hours) in temperature-
controlled (21±1°C) and humidity-controlled (55±5%)
animal facilities. Free access to food and water was pro-
vided throughout the experiment. All experimental proce-
dures were carried out in the dark phase of the cycle.
Before surgery, the rats were housed in groups of four per
cage; after surgery, the rats were individually housed. Rats
were handled daily for 3 days prior to surgery. All ex-
periments were in agreement with the Principles of Lab-
oratory Animal Care (NIH publication no. 86-23, revised
1985) and Swiss regulations for animal experiments.
Osmotic pump implantation and removal
Subjects were anesthetized with Nembutal (sodium pento-
barbital, 50 mg/kg, Abbott Labs, North Chicago, IL, USA)
and implanted with subcutaneous osmotic mini-pumps
(Alzet model 2 ML1 for AMPH at a dosage of 10 mg kg−1
day−1 or model 2001 for a dosage of 1 mg kg−1 day−1
AMPH; Alza Corporation, Palo Alto, CA, USA) along the
back, parallel to the spine, with the flow meter directed
posteriorly. Pumps were filled with either physiological
saline (SAL) or AMPH solution (Sigma Chemical Com-
pany, St. Louis, MO, USA). The concentration of the latter
was adjusted according to animal weight and pumping rate
to deliver a dosage of 1 or 10 mg kg−1 day−1. To ensure that
the pumps started dispensing immediately upon implant,
they were “primed” according to instructions from Alzet.
The pumps were filled the afternoon prior to surgery and
placed in a SAL-filled tube. This tube was placed in a 37°C
water-bath overnight. The wound was closed with stainless
steel wound clips and cleaned with an aqueous polyvinyl-
pyrrolidone (PVP)–iodine solution (Braunol 2000, Braun
B, Braun Medical AG, Switzerland). Pumps were surgi-
cally removed after 7 days using the same procedure.
For experiment 1, the groups were as follows: SAL
(n=10) and 10 mg kg−1 day−1 AMPH (n=16). In the second
experiment, rats were divided into three groups as follows:
SAL (n=12), 1 mg kg−1 day−1 AMPH (n=6) and 10 mg kg−1
day−1 AMPH (n=6).
Behavioural testing procedures and apparatus
Experiment 1
Two-way active avoidance apparatus Testing was con-
ducted in four identical shuttle boxes (Coulbourn Instru-
ments, Allentown, PA, USA; model E10-16TC). Each box
was set in a ventilated, sound- and light-attenuating shell
(model E10-20). The internal dimensions of each chamber
were 35×17×21.5 cm. The grid floor of each chamber was
divided into two identical compartments by an aluminium
hurdle (17 cm long, 4 cm high). The barrier was very thin
to prevent animals from balancing on it, thereby avoiding
shock. Foot shocks were applied to the grid floor by a
constant direct current source (model E13-14) and a scan-
ner (model E13-13) set at 0.5 mA intensity. During the
experimental session, each chamber was illuminated by a
diffuse light source (house light), mounted 19 cm above
the grid floor in the centre of the side walls. The con-
ditioned stimulus (CS) was a tone of 85 dB produced by a
speaker (model E12-02) placed behind the shuttle box on
the floor of the shell.
Active avoidance procedure The LI procedure in the two-
way active avoidance paradigm was conducted over
3 days: two consecutive daily sessions of pre-exposure
to either the tone and the apparatus or to the apparatus only
and a conditioning session on the third day.
– Withdrawal days 2 and 3
– Exposure to the tone CS and the apparatus
– The pre-exposed (PE) rats received 50 presenta-
tions of the tone with a duration of 10 s and a
mean variable inter-stimulus interval of 50 s
(range 10–90 s).
– Exposure to apparatus only
– Each non-pre-exposed (NPE) animal was con-
fined to the box with the house light on for an
equivalent period of time without any stimulus
presentation. A general evaluation of each
animal’ s activity level (PE and NPE groups)
was obtained by recording the total number of
crossings during the sessions.
228
– Withdrawal day 4
– Conditioning to the CS
– Each animal was placed into the shuttle box and
received 100 avoidance trials according to a
variable interval schedule of 50 s (ranging from 10
to 90 s). Each avoidance trial began with a 10-s
tone followed by a 2-s, 0.5-mA shock, with the
tone remaining on with each shock. If the rat
crossed the barrier to the opposite compartment
during the tone, the stimulus was terminated and
no shock was delivered (avoidance response). A
crossing response during the shock terminated
both the tone and the shock (escape response). If
the rat failed to cross during the entire tone–shock
trial, the tone and the shock terminated after 12 s
(unfinished trial). The total number of inter-trial
crossings was recorded as an additional measure
of locomotor activity.
Acoustic startle and PPI apparatus Testing was conducted
in four ventilated startle chambers (SR-LAB, San Diego
Instruments, San Diego, CA, USA), each containing a
transparent Plexiglas tube (diameter 8.2 cm, length 20 cm)
mounted on a Plexiglas frame. Noise bursts were
presented via a speaker mounted 24 cm above the tube.
Motion inside the tube was detected by a piezoelectric
accelerometer below the frame. The amplitude of the
whole body startle to an acoustic pulse was defined as the
average of one hundred 1-ms accelerometer readings
collected from pulse onset.
Acoustic startle response and PPI procedure After 6 days
of withdrawal from AMPH administration, the rats were
tested for the acoustic startle response and PPI. At the
beginning of the PPI testing session, the rats were placed
into the PPI chamber for a 2-min acclimatization period
with a 68-dB background white noise level that continued
throughout the session. After the acclimatization period,
six pulse-alone trials (two trials per pulse intensity) were
presented, comprising a 30-ms broadband burst of the
following intensities: 100, 110 and 120 dB (P100, P110
and P120, respectively). These pulse-alone trials served
to stabilize the rats’ startle response. Subsequently, 10
blocks of 16 discrete trials were presented to assess PPI.
Each block included four different trial types presented
pseudorandomly: pulse-alone (one trial for each pulse in-
tensity), prepulse-alone (one trial for each prepulse inten-
sity), prepulse followed by a pulse 100 ms after prepulse
onset (one trial for each pulse–prepulse combination) and a
single no-stimulus trial, i.e. the background noise level (one
trial). The prepulses (20 ms of broadband burst) had in-
tensities of 74, 80 and 86 dB (which correspond to +6, +12
and +18 dB above background). The session was concluded
with a final block of six consecutive pulse-alone trials (two
trials for each of the three pulse intensities). A variable
interval between the trials was used with a mean of 15 s
(ranging from 10 to 20 s).
Post-mortem monoamine measurements Animals (SAL,
n=6; AMPH, n=6) were decapitated in a drug-free state
8 days after their last drug treatment. The brains were
extracted from the skull within 1 min and placed ventral
side up in a rat brain matrix (Harvard Apparatus, South
Natick, MA, USA) on an ice-chilled plate. Double-edged
ice-cooled blades were used to prepare 2-mm-thick cor-
onal sections. The slices were placed on an ice-cold dis-
section plate for the removal of discrete brain regions,
using a 2-mm micropunch for the caudate–putamen (CPu),
medial prefrontal cortex (mPFC), amygdala, dorsal hip-
pocampus (dHippo) and ventral hippocampus (vHippo).
To dissociate nucleus accumbens (NAC) shell from core,
tissue containing the core and a small part of the anterior
commissure were first extracted using a 1-mm punch
needle, and then the tissue of the shell, surrounding the
remaining hole, was removed with a 2-mm needle. The
mPFC punch consisted primarily of its prelimbic and dorsal
infralimbic parts, whereas the amygdalar punch included
the central and basal regions of the nucleus. The CPu
punch was obtained from the dorsolateral region of the
striatum. Punch tips were pushed into the region of interest
and then withdrawn. Tissue punches from the left and right
hemispheres of each area of interest were weighed, placed
in 1.5-ml polypropylene microcentrifuge tubes containing
300 μl ice-cold 0.4 M HClO4 and homogenized using
ultrasound. After centrifugation at 10,000g for 20 min at
4°C, the clear supernatant layers were removed into a 1-ml
syringe and filtered through a 0.2-μm nylon filter to
separate the insoluble residue. This solution was immedi-
ately frozen and stored at −80°C until injection into the
high-performance liquid chromatography (HPLC) system
for the assessment of monoamines and their metabolites.
For all brain regions, with the exception of CPu and NAC
shell, an aliquot of 50 μl was injected in the HPLC system.
Due to the much higher concentration of DA in the CPu
and NAC shell, only 10 μl was injected into the column.
Chromatographic conditions An HPLC system coupled
with an amperometric electrochemical detector (Decade II;
Antec, Leyden, The Netherlands) was used to determine
concentrations of DA, dihydroxyphenylacetic acid (DO
PAC), homovanillic acid (HVA), 5-hydroxytryptamine (5-HT)
and 5-hydroxyindoleacetic acid (5-HIAA). The samples
were injected via a refrigerated autoinjector (ASI-100,
Dionex, USA) equipped with a 250 μl injection loop. The
samples were separated on a reversed-phase column
(125×3 mm glass column, Nucleosil 120-3 C 18, Knauer,
Berlin, Germany) maintained at 30°C by a column oven as
part of the electrochemical detector. An HPLC pump (P680,
Dionex, USA) connected to a pulse damper and a degasser
was used to pump the mobile phase (see below) through the
system. The working potential of the electrochemical
glassy carbon flow cell (VT-03; Antec) was +0.70 V vs an
ISAAC reference electrode. A chromatography workstation
(Chromeleon, Dionex, Olten, Switzerland) was used for
data acquisition and calculations. The mobile phase used
consisted of 250 ml of HPLC-grade acetonitrile, which was
added to 5 litres of aqueous solution containing 0.27 mM
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sodium ethylendiammoniumtetraacetate (C10H14N2O8Na2·
2H2O), 0.43 mM triethylamine (C6H15N), 8 mM potassium
chloride and 0.925 mM octanesulphonic acid (C8H17O3SNa)
that acted as an ion pairing reagent and for which pH was
adjusted to 2.95 by adding concentrated phosphoric acid.
The mobile phase was pumped through the system at a flow
rate of 0.4 ml/min. DA, 5-HTand their metabolites could be
separated in a single run of about 14 min. The positions and
heights of the peaks of the endogenous components were
compared with samples of an external calibrating standard
solution containing 1, 5, 10, 50, 100 and 500 nM of DA,
DOPAC, HVA, 5-HT and 5-HIAA.
Sensitization apparatus The apparatus for the assessment
of locomotor activity has been previously described
(Russig et al. 2003b,c). Sixteen stations (25×40×40 cm)
were used; each was equipped with a monochrome mini
video camera with a wide-angle (100°), 2.5-mm lens which
contained a sound-attenuating wooden cabin. Reversed
light–dark cycle (lights on between 1900 and 0700 hours)
was kept under the same conditions as in the animal rooms
and animals had free access to food and water throughout
the experiment. Video images were recorded by a video
recorder and later transferred to a PC with a dedicated
analysis program (Image, http://rsb.info.nih.gov/nih-image)
and macroprogram (P. Schmid, Laboratory of Behavioural
Neurobiology, Swiss Federal Institute of Technology,
Zurich, Switzerland). The percentage of changed pixels
between two adjacent 1-s images was used as measure of
activity (Richmond et al. 1998).
Sensitization procedure Animals (SAL, n=4; AMPH, n=8)
were tested for AMPH-induced locomotion. Locomotion
was assessed in 12 of the 16 test boxes and consisted of
three stages. In the first stage, each rat was weighed and
habituated to the apparatus on withdrawal day 39 at 1600
hours for a period of 18 h. On withdrawal day 40, the
animals were removed from the apparatus at 1000 hours
and injected with SAL and placed back into the apparatus
for the second stage, which consisted of 1 h of free
exploration. At 1100 hours, the animals were injected with
1.0 mg/kg AMPH and returned to the apparatus for 4 h of
free exploration.
Experiment 2
Locomotor activity and sensitization apparatus As des-
cribed above for experiment 1.
Locomotor activity procedure All animals were housed in
the animal room prior to surgery. Three hours after im-
plantation of the osmotic mini-pumps, all rats were housed
in the activity chambers for the duration of the experiment
(7 days), and locomotor activity was continuously re-
corded for 24 h a day for the entire 7-day period of SAL or
AMPH release. Animal activity was analysed following
approximately 18 h of recovery. The analysis started from
0700 hours the following morning with a 12-h dark period
(0700–1900 hours) and, thereafter, in blocks of 12 h for
five 24-h periods. We analysed 5 days of dark–light cycle
from the second day to the sixth day of drug release. On
the seventh day, the rats were taken out of the activity
chambers, and the mini-pumps were surgically removed.
After a 3-h recovery period from surgery, all animals were
transported back to the animal room.
Sensitization procedure Animals (SAL, n=12; 1 mg kg−1
day−1 AMPH, n=6; and 10 mg kg−1 day−1 AMPH, n=6)
were tested for AMPH-induced locomotion. The experi-
ment was run in two replications according to a counter-
balanced schedule, which included the factor of test boxes.
All animals (n=24) were weighed and placed in the
apparatus at 1600 hours for an 18-h habituation phase
(day 74 or 76 of withdrawal). On withdrawal day 75 or 77,
at 1000 hours, the animals were removed from the ap-
paratus, injected with SAL and placed back into the ap-
paratus for the second stage, which consisted of 1 h of free
exploration. At 1100 hours, the animals were injected with
1.0 mg/kg AMPH and returned to the apparatus for 4 h of
free exploration.
Data collection and analysis
Experiment 1
LI in an active avoidance
– Pre-exposure The total number of spontaneous crosses
was subjected to a 2×2×2 split-plot analysis of variance
(ANOVA) with the between-subjects factors of treat-
ment (SAL and AMPH) and pre-exposure (PE, NPE)
and repeated measures factor of pre-exposure day
(day 1 and day 2).
– Conditioning The 100 trials were divided into 10
blocks of 10 trials and the average number of avoidance
responses was calculated per block. These averaged
numbers of avoidance responses were submitted to a
2×2×10 split-plot ANOVA with the between-subjects
factors of treatment and pre-exposure and the repeated
measures factor of 10 blocks of 10 trial blocks.
Acoustic startle response and PPI
– Startle habituation The mean reactivity obtained in the
first block was compared against that measured in the
last block of six pulse-alone trials across the three pulse
intensities (P100, P110 and P120). For this purpose,
the average reactivity of the two pulse presentations
during the first block and the last block of six pulse-
alone trials was calculated for each pulse intensity and
submitted to a 2×3×2 (treatment×pulse intensity×
block) split-plot ANOVA consisting of a between-
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subjects factor of treatment (SAL and AMPH) and
repeated measures factors of block (first and last) and
pulse intensities (P100, P110 and P120).
– Startle reactivity The mean reactivity obtained on the
pulse-alone trials in the 10 test blocks across the three
pulse intensities was submitted to a 2×3×10 (treatment×
pulse intensity×trials) split-plot ANOVA consisting of
a between-subjects factor of treatment and repeated
measures factors of pulse intensity (P100, P110, and
P120) and pulse-alone trials (10).
– Prepulse inhibition (%PPI) The startle reactivity data
obtained from the 10 test blocks to measure PPI were
used to calculate the percent PPI (%PPI) per each pulse
intensity induced by each prepulse intensity using the
following formula: 100−[100×(startle amplitude on
prepulse plus pulse trial/startle amplitude on pulse-
alone trial)]. PPI was analysed using a 2×3×3 (treat-
ment×pulse intensity×prepulse intensity) split-plot
ANOVA consisting of a between-subjects factor of
treatment and repeated measures factors of pulse
intensity and of prepulse intensity.
– Prepulse-elicited reactivity The data of the startle
reactivity elicited by the three types of prepulse-alone
presentations plus the no-stimulus trials was first sub-
jected to natural logarithmic transformation to conform
to the homogeneity and normality assumptions of
parametric ANOVA. The data were then submitted to a
2×4 (treatment × prepulse intensity) split-plot ANOVA
with a between-subject factor of treatment (2) and a
repeated measures factor of prepulse intensity (4).
Post-mortem monoamine measurements For the analysis
of neurochemical data, the tissue concentrations of trans-
mitters and metabolites were calculated in nanograms per
milligram of wet tissue weight. Since there was no sig-
nificant difference between the right and left hemispheres,
an average of wet tissue weight was calculated from both
hemispheres of each brain region. Animals were taken
according to a counterbalanced schedule, which included
the factor of PE/NPE treatment from the LI experiment.
There was no significant pre-exposure effect. From these
values, metabolite/DA ratios (DOPAC/DA, HVA/DA) and
5-HIAA/5-HT were calculated for each individual rat.
Neurochemical data were analysed by separate one-way
ANOVAs of tissue concentrations and ratios for each
region.
Sensitization of locomotor activity Locomotor activity data
for the baseline period (last hour prior to the SAL injection)
on withdrawal day 40 and SAL challenge injection were
analysed by two separate 2×6 ANOVA with a between-
subjects factor of treatment (SAL, AMPH) and a repeated
measures factor of six 10-min blocks. The period following
the AMPH challenge injection was analysed by a 2×24
(treatment×10-min blocks) split-plot ANOVA.
Experiment 2
Locomotor activity during drug release Locomotor activity
during the 5 days of drug release was analysed by a
3×5×2×12 split-plot ANOVA. The between-subject factor
of treatment (SAL, 1 mg kg−1 day−1 AMPH and 10 mg kg−1
day−1 AMPH) and repeated measures factors of days (5),
cycle (dark, light) and hours (12).
Sensitization of locomotor activity Locomotor activity data
on withdrawal day 75 or 77 baseline period and SAL chal-
lenge injection were analysed by two separate 3×6 ANOVA
with a between-subjects factor of treatment (SAL, 1 mg kg−1
day−1 AMPH and 10 mg kg−1 day−1 AMPH) and a re-
peated measures factor of six 10-min blocks. The period
following the AMPH challenge injection was analysed by
a 3×24 (treatment×10-min blocks) split-plot ANOVA.
All statistical analyses were performed using the sta-
tistical software StatView 5.01 (SAS Institute Inc., Cary,
NC, USA) implemented on a PC using the Microsoft
Windows XP operating system. Statistical significance was
set at a probability level of p<0.05 for all tests. When main
effects or interactions were found to be significant, post




Effects of drug treatment on body weight
One-way ANOVA examining the effect of drug treatment
on body weight, expressed as percentage change over the
7 days of drug administration, revealed that AMPH-treated
animals exhibited weight loss (−6.4±1.1%) as compared
with SAL-treated animals that gained weight slightly
(+2.6±0.4%). This was supported by a significant main
effect of treatment [F(1,24)=31.12, p<0.0001, data not
shown].
LI active avoidance
Activity during the pre-exposure session on withdrawal
days 2 and 3 AMPH-treated animals were significantly
less active compared with the SAL-treated animals, as
was supported by a significant main effect of treatment
[F(1,22)=9.23, p<0.007]. A comparison of the total number
of crossings during the two pre-exposure sessions revealed
that AMPH-treated animals crossed less frequently com-
pared with SAL-treated animals on the first day of pre-
expossure (SAL 41.1±4.7 and AMPH 23.4±2.3; p<0.001)
but not on the second day of pre-exposure (SAL 21.6±2.7
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and AMPH 15.2±2.1; p>0.07). This observation was sup-
ported by a significant treatment×pre-exposure day in-
teraction [F(1,22)=8.88, p<0.007].
Conditioning session on withdrawal day 4 As can be seen
in Fig. 1, all animals improved in their avoidance re-
sponses over the 10 blocks of testing, which was supported
by a highly significant main effect of blocks [F(9,198)=19.30,
p<0.0001]. AMPH-pretreated animals showed retarded
avoidance acquisition as compared with the SAL-pretreat-
ed animals. This was reflected by a significant main effect
of treatment [F(1,22)=4.85, p<0.04]. PE animals made
fewer avoidance responses than NPE animals, as reflected
by a significant main effect of pre-exposure [F(1,22)=19.63,
p<0.0003]. As seen in Fig 1a, LI was clearly evident in
SAL-pretreated animals (restricted post hoc tests compar-
ing SAL-NPE and SAL-PE revealed, p<0.001) and was
absent in AMPH-pretreated animals (p<0.1) (Fig. 1b). The
latter was exclusively due to reduced learning demonstrat-
ed by the AMPH-NPE-treated group (post hoc tests
comparing SAL-NPE and AMPH-NPE, p<0.0001).
Acoustic startle response and PPI on withdrawal
day 6
Startle habituation Comparing the startle response in the
first block and the last block revealed a clear habituation
effect (first block>last block), as was supported by a
significant main effect of block [F(1,24)=6.98, p<0.02]. As
expected, the startle reactivity increased as a function of
the pulse intensity, reflected by a significant main effect
of pulse intensity [F(2,48)=62.53, p<0.0001]. The degree
of startle habituation was lower in the P100 condition as
compared with the P110 and P120, which was support-
ed by a significant pulse intensity×block interaction
[F(2,48)=12.60, p<0.0001]. The analysis yielded neither a
significant treatment effect nor any of its interactions (data
not shown).
Startle reactivity The mean startle reactivity during the
middle 10 pulse-alone trials increased as a function of the
pulse intensity, supported by a significant main effect of
pulse intensity [F(2,48)=88.12, p<0.0001]. With respect to
the measure of startle habituation, this reduction in startle
appeared to be more pronounced under the higher pulse
intensities, which was supported by a significant pulse
intensity×trials interaction [F(18,432)=1.79, p<0.03]. The
analysis yielded neither a significant treatment effect nor
any of its interactions (data not shown).
Prepulse inhibition (%PPI) A gradual increase in the
amount of inhibition was observed as a function of the
increasing intensity of the prepulse stimulus, which con-
stitutes the PPI effect (Koch 1999). This was support-
ed by a significant main effect of prepulse intensity
[F(2,48)=86.28, p<0.0001]. Furthermore, an inverse rela-
tionship between mean %PPI and pulse intensity was
found: an increase of the pulse intensity led to a reduction of
%PPI, as supported by the significant main effect of pulse
intensity [F(2,48)=23.67, p<0.0001] (Fig. 2). The analysis
Fig. 1 Percentage of avoidance responses made during a 100-trial
test of conditioned two-way active avoidance acquisition in animals
previously treated with either saline (SAL, a) or amphetamine
(AMPH, b). Animals were tested on AMPH withdrawal day 4.
Values are means (±SEM) from 10 blocks of 10 consecutive trials
each. NPE Non-pre-exposed, PE pre-exposed. SAL-NPE, n=6;
SAL-PE, n=4; AMPH-NPE, n=8; AMPH-PE, n=8
Fig. 2 Prepulse inhibition (PPI) expressed in terms of percentage
inhibition, calculated with reference to the respective pulse-alone
trials of a given pulse intensity and illustrated separately for the two
treatment groups. All values are means (±SEM). SAL, n=10;
AMPH, n=16
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yielded neither a significant treatment effect nor any of its
interactions.
Prepulse-elicited reactivity The 2×4 split-plot ANOVA of
the ln-transformed reactivity scores on the no-stimulus and
prepulse-alone trials revealed a significant prepulse inten-
sity effect [F(3,72)=3.30, p<0.03]. This supports the ob-
servation that the prepulse-induced reactivity increased as
a function of increasing prepulse intensities (Yee et al.
2004a,b, 2005). The analysis yielded neither a significant
treatment effect nor any of its interactions (data not
shown).
Post-mortem monoamine levels
The seven brain regions (CPu, NAC core, NAC shell,
mPFC, dHippo, vHippo and amygdala)×the eight measures
(DA, DOPAC, HVA, 5-HT, 5-HIAA, DOPAC/DA, HVA/
DA and 5-HIAA/5-HT) resulted in a total of 56 parameters,
of which only 3 parameters were significantly different
between the two treatment groups (see Table 1).
In the amygdala, the AMPH-treated animals exhibited
lower HVA levels as compared with SAL-treated animals,
which was supported by a significant main effect of
treatment [F(1,10)=10.14, p<0.01]. Moreover, the AMPH-
treated animals exhibited lower HVA/DA ratio (lower
turnover) in the amygdala as compared with the SAL-
treated animals. This observation was supported by a main
effect of treatment [F(1,10)=5.09, p<0.05]. In the mPFC,
AMPH-treated animals exhibited lower 5-HIAA levels as
compared with SAL-treated animals, as was supported by a
significant main effect of treatment [F(1,10)=6.12, p<0.04].
Expression of behavioural sensitization in response
to a 1 mg/kg AMPH challenge injection on withdrawal
day 40
Baseline stage Analysis of the last hour baseline test did
not reveal any significant difference between the AMPH
and the SAL groups (Fig. 3).
Saline stage Following an acute SAL administration, ac-
tivity increased and returned rapidly to baseline levels.
This result was supported by a main effect of 10-min blocks
[Fig. 3: F(5,50)=11.04, p<0.0001]. The analysis yielded
neither a significant treatment effect nor any interaction
involving this factor.
AMPH stage In response to the 1 mg/kg AMPH challenge
administration, all animals increased their activity levels,
followed by a steady decline in activity after the challenge
administration. This observation was supported by a
main effect of 10-min blocks [Fig. 3: F(23,230)=11.52,
p<0.0001]. The analysis revealed no influence of treat-
ment on AMPH-stimulated activity.
Experiment 2
Effects of drug treatment on body weight
One-way ANOVA examining the effect of drug treatment
on body weight expressed as percentage of change over the
7 days of drug administration revealed that rats treated with
1 and 10 mg kg−1 day−1 AMPH exhibited weight loss (−2.3±
0.5 and −7.0±0.8%, respectively) as compared with the
Table 1 DA, DOPAC, HVA, 5-HT, 5-HIAA and metabolite/neurotransmitter ratios in the caudate–putamen (CPu), nucleus accumbens
(NAC) core and shell, medial prefrontal cortex (mPFC), amygdala, dorsal hippocampus (dHippo) and ventral hippocampus (vHippo) after
8 days of withdrawal from continuous saline (SAL) or amphetamine (AMPH) administration of a dosage of 10 mg kg−1 day−1 for 7 days
(SAL, n=4; AMPH, n=8)
Region Treatment DA DOPAC HVA DOPAC/DA HVA/DA 5-HT 5-HIAA 5-HIAA/5-HT
CPu SAL 8.78±1.32 1.95±0.22 0.96±0.07 0.23±0.01 0.11±0.01 0.62±0.03 0.66±0.02 1.08±0.07
AMPH 8.73±0.55 2.00±0.11 1.14±0.08 0.23±0.02 0.13±0.01 0.49±0.05 0.57±0.04 1.19±0.07
NAC shell SAL 5.25±1.55 1.83±0.42 1.09±0.20 0.37±0.03 0.31±0.14 0.74±0.08 0.76±0.08 1.02±0.01
AMPH 5.82±1.01 1.99±0.31 0.91±0.12 0.36±0.03 0.17±0.02 0.81±0.05 0.74±0.03 0.95±0.07
NAC core SAL 5.87±1.22 2.86±0.55 2.09±0.46 0.50±0.04 0.36±0.02 0.40±0.07 0.55±0.04 1.47±0.20
AMPH 6.08±1.19 2.60±0.46 1.84±0.29 0.48±0.06 0.39±0.07 0.31±0.04 0.44±0.03 1.57±0.17
mPFC SAL 0.27±0.09 0.11±0.02 0.20±0.04 0.47±0.07 0.91±0.22 0.44±0.06 0.37±0.02 0.87±0.10
AMPH 0.16±0.02 0.08±0.01 0.23±0.07 0.48±0.03 1.50±0.44 0.36±0.03 0.31±0.01a 0.89±0.06
Amygdala SAL 0.38±0.12 0.1±0.02 0.14±0.04 0.32±0.06 0.51±0.19 0.98±0.11 0.54±0.02 0.57±0.04
AMPH 0.28±0.03 0.09±0.01 0.06±0.01a 0.31±0.01 0.22±0.01a 0.85±0.03 0.56±0.07 0.65±0.06
dHippo SAL 0.03±0.01 0.043±0.009 0.07±0.02 1.31±0.22 2.17±0.49 0.22±0.02 0.38±0.02 1.78±0.11
AMPH 0.02±0.01 0.03±0.004 0.06±0.02 1.17±0.19 2.46±0.48 0.22±0.01 0.37±0.01 1.70±0.08
vHippo SAL 0.03±0.01 0.03±0.01 0.04±0.01 1.11±0.09 1.76±0.83 0.49±0.03 0.46±0.03 0.94±0.001
AMPH 0.03±0.003 0.02±0.003 0.05±0.01 0.87±0.10 2.05±0.78 0.37±0.04 0.40±0.04 1.10±0.05
Values are expressed as nanograms per milligram of tissue weight (±SEM)
aAMPH vs SAL, p<0.03
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SAL-treated control group which gained weight slightly
(+1.0±0.3%). This was supported by a main effect of treat-
ment [F(2,21)=78.94, p<0.0001, data not shown]. Post hoc
tests revealed that 1 and 10 mg kg−1 day−1 AMPH-treated
animals exhibited significant weight loss compared with
SAL-treated animals (both p<0.0001). Moreover, the
10 mg kg−1 day−1 AMPH-treated animals lost significantly
more weight compared with the 1 mg kg−1 day−1 AMPH-
treated animals (p<0.0001).
Locomotor activity
Days 2–6 of drug release The 3×5×2×12 (treatment×days×
cycle×12 h) split-plot ANOVA revealed a significant main
effect of treatment [Fig. 4a: F(2,21)=47.07, p<0.0001]. The
10 mg kg−1 day−1 AMPH-treated animals exhibited higher
locomotor activity compared with the SAL and 1 mg kg−1
day−1 AMPH groups. The 10 mg kg−1 day−1 AMPH group
exhibited higher activity levels during the 12 h averaged
Fig. 3 Locomotor activity
measured during an initial 18-h
habituation period (only the last
hour shown), a 1-h period fol-
lowing an injection of SAL and
a 4-h period following a chal-
lenge injection of 1.0 mg/kg
AMPH. Testing was on with-
drawal day 40 in animals that
had been pretreated with a con-
tinuous AMPH, at a dosage of
10 mg kg−1 day−1 for 7 days, or
SAL. Values are means (±SEM).
SAL, n=4; 10 mg kg−1 day−1
AMPH, n=8
Fig. 4 aMean activity during the entire drug administration period.
b Locomotor activity during 5 days of drug administration. c Loco-
motor activity during a 12:12-h dark–light cycle. Values are means
(±SEM). SAL, n=12; 1 mg kg−1 day−1 AMPH, n=6; 10 mg kg−1 day−1
AMPH, n=6. *p<0.0001, #p<0.05
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over the dark–light periods as compared with SAL and
1 mg kg−1 day−1 AMPH groups. All groups exhibited
higher activity levels during the first hour of the cycle and
then activity levels declined. These observations were
supported by a significant treatment×12-h interaction
[F(22,231)=2.73, p<0.0001] and by a significant main effect
of 12 h [F(11,231)=9.58, p<0.0001]. All treatment groups
exhibited higher locomotor activity during the dark cycle
as compared with the light cycle. However, animals
treated with 10 mg kg−1 day−1 AMPH exhibited higher
locomotor activity during both the light and dark cycles as
compared with animals treated with SAL and 1 mg kg−1
day−1 AMPH (p<0.0001). Furthermore, animals treated
with 1 mg kg−1 day−1 AMPH exhibited significantly lower
activity levels during the dark cycle as compared with the
SAL-treated group (p<0.004). However, both groups
exhibited similar activity levels during the light cycle
(p>0.6). These observations were supported by a treatment×
cycle×12-h interaction [Fig. 4b: F(33,308)=2.95, p<0.02], a
significant treatment×cycle interaction [F(2,21)=5.44,
p<0.0001] and a main effect of cycle [F(1,28)=150.49,
p<0.0001].
Expression of behavioural sensitization in response
to a 1 mg/kg AMPH challenge injection on withdrawal
day 77
Baseline stage Analysis of the last hour baseline test did
not reveal any significant difference between the AMPH
and the SAL groups (Fig. 5).
Saline stage Following an acute SAL administration, ac-
tivity increased and returned rapidly to baseline levels.
This result was supported by a main effect of 10-min
blocks [Fig. 5: F(5,105)=63.68, p<0.0001].
AMPH stage In response to the 1 mg/kg AMPH challenge
administration, all animals increased locomotor activity,
followed by a steady decline in activity after the challenge
administration, as was supported by a significant main
effect of 10-min blocks [Fig. 5: F(23,483)=39.40, p<0.0001].
There was no difference between the three treatment
groups.
Discussion
This study investigated the behavioural and neurochemical
consequences of withdrawal from continuous release of
AMPH administration via subcutaneously implanted os-
motic mini-pumps. The continuous low-level administra-
tion of AMPH to animals might uniquely mimic some of
the alterations in brain chemistry that occur during psy-
chotic onset in schizophrenia. Two behavioural paradigms
that are widely employed in schizophrenia research were
examined: LI in an active avoidance paradigm and PPI
(both tested in drug-free conditions). The major findings
were that withdrawal from continuous AMPH administra-
tion disrupted LI while leaving startle response and PPI
unaffected. Behavioural sensitization in response to an
AMPH challenge was evaluated in two separate experi-
ments to test whether the expression of behavioural sen-
sitization to AMPH is strengthened by the association
of drug release with environmental cues. Expression of
behavioural sensitization was not evident in AMPH-
sensitized animals—neither when treatment was not paired
with the test environment (first experiment) nor when
treatment was paired with the test environment (second
experiment). In the post-mortem monoamine measure-
ments, seven brain regions were examined, and in each
brain region, eight parameters were measured. Significant
differences were detected only in the amygdala (reduced
Fig. 5 Animals received con-
tinuous AMPH from two differ-
ent dosages (1 and 10 mg kg−1
day−1 for 7 days) or SAL in the
activity boxes and tested for
locomotor sensitization on with-
drawal day 77 in the same boxes.
Locomotor activity measured
during an initial 18-h habituation
period (only the last hour
shown), a 1-h period following
an injection of SAL and a 4-h
period following a challenge
injection of 1.0 mg/kg AMPH.
Values are means (±SEM).
SAL, n=12; 1 mg kg−1 day−1
AMPH, n=6; 10 mg kg−1 day−1
AMPH, n=6
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HVA levels and reduced HVA/DA ratio) and in the mPFC
(reduced 5-HIAA) in the AMPH-pretreated group as
compared with the SAL-pretreated group.
We employed a continuous AMPH administration sched-
ule that was recently used in the context of an animal model
of depression (Cryan et al. 2003; Paterson et al. 2000).
These studies have demonstrated that this schedule induced
more pronounced anhedonia, as expressed by higher re-
ward thresholds during the first few days of drug with-
drawal, as compared with withdrawal from repeated AMPH
administration (Lin et al. 1999). Our hypothesis was that
like the situation within the framework of an animal model
of depression, continuous AMPH treatment will induce a
more pronounced withdrawal effect which might attenuate
both LI and PPI. However, while observing a clear dis-
ruption of LI, we obtained an intact PPI phenomenon. It
could be argued that if the animals had been tested for PPI
earlier, we would have seen a disruption. However, un-
published results from animals that were exposed to an
identical AMPH administration schedule have shown no
such trend (Peleg-Raibstein et al., unpublished results).
Disrupted LI and intact PPI are similar to what we observed
previously with an ESC AMPH schedule (Murphy et al.
2001b; Russig et al. 2002, 2003b). It should be pointed out
that both AMPH administration schedules were almost
equivalent in the total AMPH dose (70 in the continuous
schedule vs 75 mg/kg in the ESC schedule). Where the two
AMPH schedules do differ is in their ability to induce
expression of behavioural sensitization in response to a low
dose of AMPH. While the ESC AMPH schedule clearly
leads to behavioural sensitization in AMPH-treated ani-
mals (Russig et al. 2003a,c, 2005), the continuous AMPH
administration does not (Post 1980; Robinson and Becker
1986). Behavioural sensitization was not expressed in
response to a challenge injection of AMPH on day 40 of
withdrawal (experiment 1) in AMPH continuously-treated
animals. It is known that longer withdrawal periods lead to
more augmented sensitization effect (Robinson and Becker
1986) and that the expression of sensitization may be
context-dependent (Badiani et al. 1997; Browman et al.
1998; Robinson et al. 1998). Therefore, in the second
experiment, animals were tested for the expression of
sensitization on withdrawal day 77 using the same test
environment as the one used for drug delivery during the
induction phase. Even though it appeared graphically
(Fig. 5) that the 10 mg kg−1 day−1 AMPH group exhibited
some behavioural sensitization as compared with the
control and 1 mg kg−1 day−1 AMPH groups, these changes
were far from statistically significant. The current results
support and extend previous findings that continuous
release, as opposed to repeated discrete AMPH injections,
does not lead to the expression of behavioural sensitization
(Post 1980; Robinson and Becker 1986).
In addition to our failure (in line with previous reports in
the literature) to reveal expression of sensitization follow-
ing continuous AMPH administration, the present study is
the first to examine locomotor activity during the entire
drug-release period of AMPH delivered by osmotic mini-
pumps. We employed a highly sensitive method of detec-
tion of locomotor activity, continuously recording each
second 24 h a day (Russig et al. 2003c). The augmentation
of locomotor activity was dose dependent, as animals
treated with 10 mg kg−1 day−1 AMPH exhibited marked day
and night hyperactivity compared with the SAL and 1 mg
kg−1 day−1 AMPH-treated animals. The mean locomotor
activity across days and cycles of the 1 and 10mg kg−1 day−1
AMPH-treated animals gradually declined from the second
day to the last day of treatment. In contrast, activity levels of
the SAL-treated animals remained unchanged for the du-
ration of the experiment. This decreased activity observed in
the AMPH-treated animals may be attributed to tolerance to
the motor stimulant effect of AMPH with continuous
exposure (Nielsen et al. 1980).
LI was clearly demonstrated in the SAL group as the
NPE animals made more avoidance responses than the PE
animals. Conversely, in the withdrawn AMPH group, an
attenuation of LI was observed that was largely due to
impaired avoidance learning exhibited by the AMPH-NPE
as compared with the SAL-NPE group. We have seen
before that LI disruption is not necessarily due to improved
learning in the AMPH-PE group only but can also be due to
impaired learning in the AMPH-NPE group (Murphy et al.
2001b). Furthermore, this phenomenon was also demon-
strated in acute schizophrenic patients where the PE sub-
jects learned faster than the NPE subjects (Baruch et al.
1988). Hence, the observed LI attenuation, due to impaired
learning in the AMPH-NPE group, might partially mimic
these (perhaps cognitive) deficits observed in schizo-
phrenia patients since poor learning has been suggested to
contribute to the LI deficits of schizophrenia patients
(Green et al. 2000; Swerdlow et al. 1996). Alternatively, it
can be suggested that the poor avoidance performance in
the AMPH-NPE group can reflect a phenomenon called
“learned helplessness” since similar behavioural learning
deficits have been described in the literature after exposure
to inescapable shocks (Anisman and Zacharko 1990). The
reduced avoidance of the AMPH-NPE group may indicate
a depressive state similar to that seen in reductions of
reward-motivated behaviours reported following short pe-
riods of withdrawal from AMPH (Barr et al. 1999; Barr and
Phillips 1999; Lin et al. 1999). One measure clearly re-
flecting learned helplessness is an enhanced number of
escape failures (sometimes referred to as unfinished trials)
(Overmier and Seligman 1967; Vollmayr and Henn 2001).
However, the SAL-NPE (2.0±0.9) animals did not differ
from the AMPH-NPE (4.1±1.2) animals in terms of
unfinished trials. Since our data did not reveal an effect
of AMPH withdrawal on unfinished trials, we can safely
conclude that learned helplessness cannot account for the
observed results. This conclusion is in line with previous
findings from our laboratory which did not find an effect of
withdrawal from an ESC AMPH schedule on learned
helplessness (Russig et al. 2003c).
In the current study, we employed a recently developed
PPI protocol to enhance the detection sensitivity of PPI
disrupting treatments (Yee et al. 2005). To achieve this
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goal, this PPI paradigm manipulates the pulse intensity by
using three levels of intensities (i.e. 100, 110 or 120 dB), as
compared with the conventional PPI paradigm that em-
ploys a single pulse intensity (Murphy et al. 2001b; Russig
et al. 2003b). In line with previous observations (Pothuizen
et al. 2006; Yee et al. 2005), our results clearly demonstrate
that the magnitude of %PPI is not only a function of
increasing prepulse intensities but is also affected by
changes in intensity of the pulse stimulus. The weakest
pulse stimulus of 100 dB was associated with the highest
level of mean %PPI, which constitutes a confirmation of
previous observations using this paradigm. We expected
that this new PPI procedure would reveal a PPI disruption
that would not have been observed using the conventional
PPI procedure. Despite employing a more sensitive PPI
program, we observed no difference between treatment
groups (SAL and AMPH), in %PPI, or in startle reactivity.
As the AMPH schedule had showed LI attenuation (in
experiment 1), we examined one subgroup of animals in
post-mortem neurochemistry with the aim of unravelling
the underlying neurochemical mechanisms of disrupted LI
by comparing it to the SAL-treated animals. On withdrawal
day 8, we did not find DA depletion in either the CPu or in
the NAC. Our results are in contrast to neurochemical
studies that have shown that continuous release, albeit of
higher AMPH doses, as compared with repeated intermit-
tent or ESC AMPH administration, has a selective neu-
rotoxic effect on DA terminals in the CPu (Ellison et al.
1996; Gately et al. 1987; Ricaurte et al. 1984; Ryan et al.
1990). However, the current results are in line with our
previous findings that withdrawal from intermittent and
ESC AMPH schedules did not lead to any significant neu-
rochemical changes as compared with SAL treatment
(Murphy et al. 2003). It seems that the dosage of 10 mg
kg−1 day−1 over 7 days did not lead to an enduring
depletion or neural damage in the striatum of Wistar rats.
There are a number of factors that determine the extent to
which the neurotoxic effects of continuous AMPH treat-
ment are regionally and neurochemically specific, which
include dose used, duration of treatment, age of the or-
ganism, prior drug history and species (Robinson and
Becker 1986). The only significant effects that emerged
from the neurochemistry post-mortem experiment were
reduced levels of 5-HIAA in the mPFC in the pretreated
AMPH animals. In the amygdala, AMPH-pretreated ani-
mals exhibited reduced HVA levels and reduced turnover
indicated by reduced HVA/DA ratio. Perhaps one can relate
the findings in the amygdala to the well-established
retardation of active avoidance learning acquisition in-
duced by amygdala lesions (Coover et al. 1973; Werka and
Zielinski 1998). Furthermore, clinical evidence suggested
the mPFC abnormalities are involved in the pathopysiol-
ogy of depression (Drevets et al. 1997; Mann et al. 1996;
Williams et al. 2004). This may explain our findings of
reduced 5-HIAA, the serotonin metabolite, in the mPFC.
Conclusion
The present study represents the first report investigating
the effects of withdrawal from continuous AMPH release
on LI and PPI. Continuous AMPH release, unlike ESC
AMPH administration, has not led to any signs of sen-
sitization either in the induction or in the expression eval-
uation. We have found that the LI deficits observed
following continuous AMPH administration are similar to
those following ESC administration. Furthermore, both
continuous and ESC AMPH regimes did not affect PPI.
Thus, based on the results of the current study, sensitization
cannot be seen as a prerequisite to LI disruption, a con-
clusion which may have been drawn from the ESC AMPH
studies. Future studies should further explore the neuro-
biological mechanisms by which the different AMPH
treaments induce disruption of LI and the underlying
mechanisms that are responsible for these deficits.
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